drug
netarsudil mesylate
Marketedupdated 5mo agoby $ALC ALCON INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying netarsudil mesylate
- phase4Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
- phase4Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
- phase2Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 27, 2030
~3.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Mar 14, 2034compositionUS 10588901
- Mar 14, 2034method-of-use (U-1524)US 11020385
- Mar 14, 2034formulationUS 11185538
- Mar 14, 2034compositionUS 9415043
- Mar 14, 2034compositionUS 9931336
- Nov 10, 2030compositionUS 83948264.1y
- Jan 27, 2030compositionUS 101740173.3y
- Jan 27, 2030compositionUS 106548443.3y
- Jan 27, 2030method-of-use (U-1524)US 110280813.3y
- Jan 27, 2030method-of-use (U-1524)US 116187483.3y
- Jul 11, 2026method-of-use (U-1524)US 10532993
- Jul 11, 2026method-of-use (U-1524)US 10882840
- Jul 11, 2026method-of-use (U-1524)US 11021456
- Jul 11, 2026compositionUS 8450344
- Jul 11, 2026compositionUS 9096569
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that